Summer Sale
50% off Premium Yearly
Opinions Lorne Steinberg
ViatrisVTRSTOP PICKDec 22, 2020
Lorne SteinbergStock price when the opinion was issued
As of Jun 18, 2026. Market Open.
You might be interested:
;fill-opacity:1;'/%3e%3cpath%20d='M31%2018.6001V30H8V18.6001L14.1334%2022.4334L19.4999%2014L24.8669%2022.4334L31%2018.6001Z'%20fill='%23EE5432'%20style='fill:%23EE5432;fill:color(display-p3%200.9340%200.3310%200.1956);fill-opacity:1;'/%3e%3c/svg%3e){kind=small}
Premium contentThe pharma company produces Lipitor as one of its brands. It has embarked on a divestiture strategy that is allowing it to focus on core competencies and reduce costs. The are on target for $450 million in new product launches. It trades at 7x earnings and below book value. Cash reserves are growing as debt is aggressively retired. Its dividend is backed by a payout ratio under one-third of cash flow. We recommend placing a stop-loss at $8.50, looking to achieve $41 -- upside potential of 30%. Yield 4.5%
(Analysts’ price target is $14.11)
Share price flat, but owns shares.
Excellent business within healthcare sector.
Getting into new business lines.
4% dividend yield with lots of free cash flow.
Share buybacks good for shareholders.
Trading at 4x earnings.
Lorne Steinberg
It is the cheapest stock in their portfolio at 4X earnings, a pharma company formed by a joint venture. Its investment grade bond issues are in rock solid shape. It sold a division for $2 billion and will use the cash for a couple of acquisitions in eye wear and to buy back stock. There are potential sales of other smaller divisions so there could be more buybacks plus paying down debt. The dividend yield is 4.1%. Has a low price due to a couple of disappointing quarters but numbers have been solid since. Also revenues have been flat-lining.
Buy 4 Hold 10 Sell 0
Lorne Steinberg
Lorne SteinbergLorne SteinbergLorne SteinbergLorne Steinberg
Lorne SteinbergLorne SteinbergLorne Steinberg
Brand new company from the merger if Mylan and Upjohn. Trades at 6x earnings and nobody has covered this. This stock will trade at 10-11x earnings, nearly doubling. This is his most compelling top pick today. The company is already generating profits and cash flow. They make Xoloft, Viagra, Lipotor mostly from Upjohn. They also have a pipeline of new drugs company. Seasoned managers. (Analysts’ price target is $22.43)